Gdue®

NEW AND MAJOR **REAL-LIFE** STUDY ON A **NUTRACEUTICAL**

505 SUBJECTS INVOLVED

"Effectiveness of Ascophyllum nodosum and Fucus vesiculosus on Metabolic Syndrome Components: A Real-World,Observational Study"

Journal of Diabetes Research - September 2021

Antonio Nicolucci, Maria Chiara Rossi e Massimiliano Petrelli

CONCLUSIONS

6 MONTHS OF TREATMENT WITH GDUE HAS A FAVOURABLE IMPACT ON **ALL THE COMPONENTS OF THE METABOLIC SYNDROME**

CARDIOVASCULAR RISK WAS DECREASED
RRR -27,7% p<0,0001

ÆSCULAPIUS
FARMACEUTICI

WHY IS **GDUE** EFFECTIVE?



Gabbia et al. Fucus vesiculosus and Ascophyllum nodosum Ameliorate Liver Function by Reducing Diet-Induced Steatosis in Rats. Marine Drugs 2020

REDUCES PEAKS OF POSTPRANDIAL BLOOD GLUCOSE LEVEL

NO HYPOGLYCAEMIC PEAKS

INCREASED SENSE OF SATIETY AS A RESULT OF PROLONGED AVAILABILITY OF CARBOHYDRATES

ACTING ON THE METABOLISM OF CARBOHYDRATES HELPS TO DECREASE CARDIOVASCULAR RISK AS THIS HAS AN IMPACT ON THE DIFFERENT COMPONENTS OF THE METABOLIC SYNDROME

Journal of Diabetes Research

REAL-LIFE

505

SUBJECTS INVOLVED WHO SUFFER FROM **METABOLIC SYNDROME**

6 MONTHS

OF TREATMENT

RRR -27,7%

CARDIOVASCULAR RISK WAS DECREASED

p<0,0001

STATISTICS HAVE **CLEARLY DEMONSTRATED** THAT **6 MONTHS** OF TREATMENT WITH **GDUE** ENSURES:

BODY WEIGHT IS REDUCED

Statistics show a significant reduction in body weight after 90 and 180 days **regardless of the type of diet.**

-7,3 Kg p <0.0001



WAIST CIRCUMFERENCE IS REDUCED

Statistics show a significant reduction in waist circumference after 90 and 180 days **regardless of the type of diet.**

-7,5 cm p <0.0001



HbA1c and FASTING BLOOD GLUCOSE ARE REDUCED

in the sub-group of the **197** dysglycemic subjects and in the sub-group of the **136** diabetic subjects

HbA1c
-0,55% p <0.0001

Fasting blood glucose
-16,3 mg/dL p <0.0001

DYSGLYCEMIC SUBJECTS





DIABETIC SUBJECTS





LDL and TRIGLYCERIDES ARE REDUCED and HDL IS INCREASED

in the sub-group of the **84** dysglycemic subjects

LDL
-18,2 mg/dL p <0.0001

HDL
+2,9 mg/dL p <0.0001

Triglycerides
-39 mg/dL p= 0.009

LDL



HDL



TRIGLYCERIDES



HYPERTENSION IS REDUCED

in the sub-group of the **210** hypertensive subjects

Systolic pressure
-7,1 mmHg p <0.0001

Diastolic pressure
-4,2 mmHg p <0.0001

SYSTOLIC BLOOD PRESSURE



DIASTOLIC BLOOD PRESSURE



IGNIFICANT REDUCTION OF **HOMA-IR INDEX**
SIGNIFICANT REDUCTION IN **FASTING PLASMA INSULIN**

THE EFFECTIVE NUTRACEUTICAL

A DIETARY ALLY FOR PATIENTS SUFFERING FROM OVERWEIGHT, OBESITY, DYSGLYCEMIA, DIABETES, AND CARDIOVASCULAR RISK (METABOLIC SYNDROME)

→ REDUCES POSTPRANDIAL BLOOD GLUCOSE

→ DOES NOT INDUCE HYPOGLYCAEMIA

1 CAPSULE
BEFORE THE MAIN MEALS (2/3 CAPSULES/DAY)

GLUTEN FREE

Inhibition of α-amylases and α-glucosidase is reversible and non-competitive.
Gdue ensures a high level of tolerability.

AVERAGE QUANTITY

	Per 1 capsule	% VNR* 1 capsule	Per 3 capsules	% VNR* 3 capsules
Ascophyllum nodosum	237,5 mg	-	712,5 mg	-
Fucus vesiculosus	12,5 mg	-	37,5 mg	-
Cromo	7,5 mcg	18,8	22,5 mcg	56,3

*NRV: Nutrient reference values
One capsule contains up to a maximum of 75 mcg of iodine.

Recommended price € 28.50 (€ 0.95/1.42 per day depending on the number of administrations/day)

AE_VIS_Gdue_EN_10-2021_001

www.gdue.org
www.aesculapius.it

ÆSCULAPIUS FARMACEUTICI

Via Cefalonia 70 - 25124 Brescia - ITALY
+39 030 3532013
info@aesculapius.it